250 related articles for article (PubMed ID: 18192510)
1. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
Ataga KI; Smith WR; De Castro LM; Swerdlow P; Saunthararajah Y; Castro O; Vichinsky E; Kutlar A; Orringer EP; Rigdon GC; Stocker JW;
Blood; 2008 Apr; 111(8):3991-7. PubMed ID: 18192510
[TBL] [Abstract][Full Text] [Related]
2. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW;
Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872
[TBL] [Abstract][Full Text] [Related]
3. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.
Ataga KI; Stocker J
Expert Opin Investig Drugs; 2009 Feb; 18(2):231-9. PubMed ID: 19236269
[TBL] [Abstract][Full Text] [Related]
4. Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD003426. PubMed ID: 30338520
[TBL] [Abstract][Full Text] [Related]
5. Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2016 Mar; 3():CD003426. PubMed ID: 26942338
[TBL] [Abstract][Full Text] [Related]
6. Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2012 Jul; (7):CD003426. PubMed ID: 22786485
[TBL] [Abstract][Full Text] [Related]
7. Senicapoc trial results support the existence of different sub-phenotypes of sickle cell disease with possible drug-induced phenotypic shifts.
Castro OL; Gordeuk VR; Gladwin MT; Steinberg MH
Br J Haematol; 2011 Dec; 155(5):636-8. PubMed ID: 21732927
[No Abstract] [Full Text] [Related]
8. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice.
Stocker JW; De Franceschi L; McNaughton-Smith GA; Corrocher R; Beuzard Y; Brugnara C
Blood; 2003 Mar; 101(6):2412-8. PubMed ID: 12433690
[TBL] [Abstract][Full Text] [Related]
9. Drugs for preventing red blood cell dehydration in people with sickle cell disease.
Nagalla S; Ballas SK
Cochrane Database Syst Rev; 2010 Jan; (1):CD003426. PubMed ID: 20091545
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the potassium channel K
Staal RGW; Khayrullina T; Zhang H; Davis S; Fallon SM; Cajina M; Nattini ME; Hu A; Zhou H; Poda SB; Zorn S; Chandrasena G; Dale E; Cambpell B; Biilmann Rønn LC; Munro G; Mӧller T
Eur J Pharmacol; 2017 Jan; 795():1-7. PubMed ID: 27876619
[TBL] [Abstract][Full Text] [Related]
11. Repurposing the K
Lee RD; Chen YJ; Nguyen HM; Singh L; Dietrich CJ; Pyles BR; Cui Y; Weinstein JR; Wulff H
Transl Stroke Res; 2024 Jun; 15(3):518-532. PubMed ID: 37088858
[TBL] [Abstract][Full Text] [Related]
12. Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial.
Ataga KI; Staffa SJ; Brugnara C; Stocker JW
Br J Haematol; 2021 Mar; 192(5):e129-e132. PubMed ID: 33527340
[No Abstract] [Full Text] [Related]
13. Anti-haemolytic effect of senicapoc and decrease in NT-proBNP in adults with sickle cell anaemia.
Minniti CP; Wilson J; Mendelsohn L; Rigdon GC; Stocker JW; Remaley AT; Kato GJ
Br J Haematol; 2011 Dec; 155(5):634-6. PubMed ID: 21651507
[No Abstract] [Full Text] [Related]
14. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
[TBL] [Abstract][Full Text] [Related]
15. Novel inhibitors of the Gardos channel for the treatment of sickle cell disease.
McNaughton-Smith GA; Burns JF; Stocker JW; Rigdon GC; Creech C; Arrington S; Shelton T; de Franceschi L
J Med Chem; 2008 Feb; 51(4):976-82. PubMed ID: 18232633
[TBL] [Abstract][Full Text] [Related]
16. Erythrocytes from hereditary xerocytosis patients heterozygous for KCNN4 V282M exhibit increased spontaneous Gardos channel-like activity inhibited by senicapoc.
Rivera A; Vandorpe DH; Shmukler BE; Gallagher DR; Fikry CC; Kuypers FA; Brugnara C; Snyder LM; Alper SL
Am J Hematol; 2017 Jun; 92(6):E108-E110. PubMed ID: 28295477
[No Abstract] [Full Text] [Related]
17. Dose-escalation study of ICA-17043 in patients with sickle cell disease.
Ataga KI; Orringer EP; Styles L; Vichinsky EP; Swerdlow P; Davis GA; Desimone PA; Stocker JW
Pharmacotherapy; 2006 Nov; 26(11):1557-64. PubMed ID: 17064199
[TBL] [Abstract][Full Text] [Related]
18. The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity.
Tubman VN; Mejia P; Shmukler BE; Bei AK; Alper SL; Mitchell JR; Brugnara C; Duraisingh MT
Antimicrob Agents Chemother; 2016 Jan; 60(1):613-6. PubMed ID: 26459896
[TBL] [Abstract][Full Text] [Related]
19. Senicapoc: a potent candidate for the treatment of a subset of hereditary xerocytosis caused by mutations in the Gardos channel.
Rapetti-Mauss R; Soriani O; Vinti H; Badens C; Guizouarn H
Haematologica; 2016 Nov; 101(11):e431-e435. PubMed ID: 27443288
[No Abstract] [Full Text] [Related]
20. Targeting K
Todesca LM; Maskri S; Brömmel K; Thale I; Wünsch B; Koch O; Schwab A
Cell Physiol Biochem; 2021 May; 55(S3):131-144. PubMed ID: 34043300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
